Free Trial
NYSE:NAVB

Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis

Navidea Biopharmaceuticals logo

About Navidea Biopharmaceuticals Stock (NYSE:NAVB)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
60,283 shs
Average Volume
7,146 shs
Market Capitalization
$10 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NAVB Stock News Headlines

Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
$3,600 gold is nice ... but here’s what most gold bugs are missing
Gold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.tc pixel
See More Headlines

NAVB Stock Analysis - Frequently Asked Questions

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The company earned $0.10 million during the quarter, compared to the consensus estimate of $0.60 million.

Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Navidea Biopharmaceuticals investors own include Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), CorMedix (CRMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), Advanced Micro Devices (AMD) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/10/2021
Today
10/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:NAVB
CIK
810509
Employees
10
Year Founded
1983

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$8.13 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
100,080,000
Free Float
56,367,000
Market Cap
$10 thousand
Optionable
Optionable
Beta
1.76

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NYSE:NAVB) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners